



## **PharmaMar Group Announces Financial Results for Full Year 2015**

- **The Group reported record revenues of €194 million (+11% YoY)**
- **Net sales of Yondelis® increased by 15% in 2015 to €88.4 million**
- **PharmaMar increased R&D spending by 21% due to advancement of its clinical programs**

**Madrid, 29 February 2016** – PharmaMar today announced its Full Year 2015 financial results. The Group's revenues totalled €193.8 million in 2015, the highest ever top-line reading and an increase of 11% with respect to 2014. This figure was boosted by 15% growth in net sales of Yondelis®, to €88.4 million in 2015, the best year for Yondelis® sales since the drug was approved in 2007. Overall, the group's biopharmaceutical area ended 2015 with €94.6 million in net sales, a 15% year-on-year increase.

Net sales in the consumer chemicals segment also expanded, by 3% to €67.3 million, in 2015.

Other revenues, which include licence fees, royalties and other service charges, amounted to €31.8 million in 2015, an 18% increase with respect to 2014.

Research and development expenditure increased by 21% in 2015 to €63.5 million (€52.4 million in 2014). R&D spending was focused mainly in oncology, principally for clinical development of PM1183. PharmaMar is currently conducting pre-clinical and clinical trials with this molecule in a number of solid tumour indications, including a Phase III registration trial in platinum-resistant ovarian cancer, recruitment for which commenced in the second half of the 2015. The company also plans to start another pivotal Phase III trial with PM1183 in 2016 in the treatment of small-cell lung cancer (SCLC).

As a result, PharmaMar group EBITDA amounted to €19.4 million in 2015 (vs. €25.7 million in 2014) and net profit amounted to €6.5 million (€13 million in 2014).



During the year, the Company refinanced over €30 million of short-term debt, which improved its debt structure and released funds to continue investing in R&D. At 31 December 2015, net debt amounted to €46.9 million, compared with €54.8 million at the end of 2014.

#### **About PharmaMar**

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other three clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at [www.pharmamar.com](http://www.pharmamar.com).

#### **Disclaimer**

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

#### **Further information from:**

##### **Communication:**

Paula Fernández – Media Relations Manager  
[pfalarcon@pharmamar.com](mailto:pfalarcon@pharmamar.com)  
Mobile: +34 638796215  
Landline: +34 918466000



##### **Investors:**

Phone: +34 914444500

For more information, visit our website: [www.pharmamar.com](http://www.pharmamar.com)